6.010USD+6.010盤後交易 08/03, 20:00 (美東)
關鍵數據
6.010今開
6.010最高
608.88K成交量
虧損本益比TTM
23.63本益比動
--股利TTM
0.92%換手率
6.010昨收
5.720最低
2.41M成交額
虧損本益比靜
-13.36市淨率
0.00%股息率 TTM
-20.01%ROA
10.62052週最高
0.98量比
-50.42M淨利潤
65.84M總股本
-0.6682每股盈餘TTM
1.34Beta
-18729.61%ROE
3.86052週最低
4.82%振幅
64.27%毛利率
384.59M總市值
-4.21回報/風險
3.33%風險率
操作建議
Evolus Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名34/155位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為14.67。中期看,股價處於平穩狀態。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
Evolus Inc新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Evolus Inc簡介
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
公司代碼EOLS
公司Evolus Inc
CEOMoatazedi (David)
網址https://www.evolus.com/
公司股東
常見問題
Evolus Inc(EOLS)的當前股價是多少?
Evolus Inc(EOLS)的當前股價是 5.84。
Evolus Inc股票的52週最高點是10.62。
Evolus Inc股票的52週最低點是3.86。
現在Evolus Inc(EOLS)的股票是買入、持有還是賣出?
根據分析師評級,Evolus Inc(EOLS)的總體評級為買入,目標價格為14.67。
Evolus Inc(EOLS)股票的每股收益(EPS TTM)是多少
Evolus Inc(EOLS)股票的每股收益(EPS TTM)是-0.80。